Atrial natriuretic peptide (ANP) and transforming growth factor (TGF)-β play important counterregulatory roles in pulmonary vascular adaptation to chronic hypoxia.
INTRODUCTION
Hypoxia-induced pulmonary hypertension and vascular remodeling result from an imbalance in the normal relationships between vasoconstrictor and vasodilator and between mitogenic and growth inhibiting pathways in the pulmonary vasculature. Our previous studies in rodent models have provided convincing evidence that endogenous atrial natriuretic peptide (ANP) and transforming growth factor (TGF)-β play important counterregulatory roles in pulmonary vascular adaptation to chronic hypoxia (3, 29) .
ANP and TGF-β expression are upregulated in heart and lung, respectively, of hypoxia adapted animals (1, 2, 26, 29) . The functional significance of the hypoxia-induced increase in ANP is supported by observations of worsening pulmonary hypertension and vascular remodeling in ANP deficient (Nppa-/-) mice compared to wild type controls in response to hypoxic stress (29). Our recent studies in a novel mouse model that expresses an inducible dominant negative mutation of the TGF-β receptor type II gene (DnTGFβRII), and thus cannot activate the TGF-β-Smad signaling cascade, demonstrate that disruption of TGF-β signaling greatly attenuates hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, pulmonary arterial remodeling and muscularization, and expression of extracellular matrix (ECM) in lung, supporting a critical role for TGF-β signaling in the pathogenesis of chronic hypoxia-induced pulmonary hypertension and vascular remodeling (3) .
ANP, via activation of guanylate cyclase-coupled membrane receptors, increases intracellular cGMP levels and activates cGMP-dependent protein kinase (PKG), with resultant growth inhibiting and antiproliferative effects in a variety of cell types, including pulmonary arterial smooth muscle cells (PASMCs) (2, 10, 22) . In contrast, activated TGFPage 4 of 37 β participates in pulmonary morphogenesis and in the pathogenesis of pulmonary fibrosis and vascular remodeling by stimulating PASMC proliferation and ECM expression (1, 23, 33) . TGF-β signals through membrane bound heteromeric type I (TGFβRI) and type II (TGFβRII) receptor kinases that transduce intracellular signals via phosphorylation and nuclear translocation of receptor-activated Smad2 and Smad3 proteins, which modulate the transcription of a large number of genes (20, 28) . The molecular mechanisms of the counterregulatory effects of ANP-cGMP-PKG signaling on activated TGF-β-induced Smad signaling in PAMSCs have not been studied.
In the present study, we tested the hypothesis that ANP signaling inhibits TGF-β1-stimulated ECM expression in isolated PASMCs and probed the specific site(s) at which molecular merging of these pro-and anti-fibrogenic signaling cascades occurs.
Specifically, we tested whether ANP-cGMP-PKG signaling interrupts downstream events in the TGF-β1 signaling pathway by inhibiting TGF-β1-induced phosphorylation of Smad2 and Smad3 proteins and/or preventing nuclear translocation of phosphorylated Smad2 and Smad3.
MATERIALS AND METHODS

Animals and cell culture
Young adult (8 wk old) male Sprague-Dawley rats (Charles River Breeding Laboratories, Wilmington, MA) were used. All experimental protocols were approved by the University of Alabama at Birmingham (UAB) IACUC Committee and were consistent with the NIH Guide for the Care and Use of Laboratory Animals (DHEW Publication No.
96-01, 1996).
Page 5 of 37
PASMCs were isolated from distal segments of pulmonary arteries (2nd-3rd branches, 0.1-0.2 mm external diameter) using the explant method described previously (14, 15, 30) . To confirm the characteristics of smooth muscle cells (SMCs) in culture, immunohistochemical staining of α-SMC actin was performed using selective α-SMC actin antibody and secondary horse radish peroxidase-labeled anti-IgG antibodies. All cultures were examined by phase contrast microscopy before and after each experimental period to assess cell viability. PASMCs were used for experiments at passage 3 or 4.
Prior to each study, PASMCs were grown in 10% fetal bovine serum (FBS)-DMEM to 95% confluence and then made quiescent by placing them in medium containing 0.1% FBS for 24 hrs. For Northern, real-time quantitative RT-PCR or Western blot analyses, PASMCs were cultured in 60-mm cell culture dishes. For quantitative analysis of nuclear translocation of phosphorylated Smad2 (pSmad2) and Smad3 (pSmad3), PASMCs were cultured on 18 mm x 18 mm glass cover slides.
Experimental protocols Experiment 1: Effects of ANP signaling on TGF-β1-stimulated ECM expression
To test the hypothesis that ANP and cGMP inhibit TGF-β1-stimulated expression of mRNA for the extracellular matrix (ECM) proteins periostin (PN), osteopontin (OPN) and plasminogen activator inhibitor 1 (PAI-1, a biomarker of TGF-β1 action in cells), quiescent PASMCs were treated with TGF-β1 (0.1 to 5 ng/ml) (Sigma) for 24 hrs with or without pretreatment with ANP (1 µM) (Sigma), cGMP (8-Br-cGMP, 1 mM) (Sigma), and/or PKG inhibitors KT5823 (1 µM) (CalBiochem) or Rp-8-Br-cGMP (50 µM) (Alexis) for 30 min. PASMCs were then harvested for Northern blot, real time quantitative RT-PCR, or Western blot analyses.
Experiment 2: Effects of TGF-β1 and cGMP on phosphorylation of Smad3 and
Smad2 proteins in PASMCs
To test the hypothesis that cGMP inhibits TGF-β1-induced phosphorylation of Smad2 and Smad3 in PASMCs, quiescent PASMCs were pretreated with cGMP (0.01 to 1 mM) or vehicle for 30 min before addition of TGF-β1 (1 ng/ml) to the medium and incubation for an additional 30 min. After treatment with TGF-β1 and/or cGMP, cells were harvested for assessment of pSmad2, pSmad3 and Smad4 (internal control that cannot be phosphorylated) levels using Western blot analysis.
Experiment 3: Effects of ANP/cGMP on TGF-β1-induced nuclear translocation of pSmad2 and pSmad3 in rat PASMCs
To test the hypothesis that inhibition of TGF-β1-stimulated ECM expression by ANP-cGMP-PKG signaling is dependent on events downstream from phosphorylation of Smad2 and Smad3, we examined the effects of ANP and cGMP on TGF-β1-stimulated nuclear translocation of pSmad2 and pSmad3 in PASMCs. Quiescent rat PASMCs were pretreated with ANP (1 µM), cGMP (1 mM) or vehicle for 30 min, and then exposed to TGF-β1 (1 ng/ml) for an additional 5 min to 6 hr. PASMCs were fixed in 4% paraformaldehyde and permeablized in 0.1% Triton X100 in PBS. The fixed PASMCs were stained with selective anti-pSmad2, anti-pSmad3, and anti-Smad4 primary antibodies and a Texas Red-labeled donkey anti-rabbit IgG secondary antibody (Jackson ImmunoResearch Lab) to assess nuclear translocation of pSmad2 and pSmad3 using confocal fluorescence microscopy with a computerized Zeiss-Axioskop system.
Experiment 4: Effects of ANP and cGMP on PKG activity in rat PASMCs
To test the hypothesis that ANP and/or cGMP activates PKG in rat PASMCs, quiescent PASMCs were pretreated with PKG inhibitors KT5823 (1 µM) or Rp-8-BrcGMP (50 µM), or vehicle for 15 min before adding ANP (1 µM) or cGMP (1 mM).
Fifteen min after beginning treatment with ANP or cGMP, cells were exposed to TGF-β1
(1 ng/ml) for an additional 15 min. Cells were then harvested for PKG activity measurement.
Experiment 5: ANP/cGMP signaling inhibits TGF-β1-induced nuclear translocation of pSmad2 and pSmad3 in rat PASMCs by activating PKG in rat PASMCs.
To test the hypothesis that ANP/cGMP signaling inhibits TGF-β1-induced nuclear translocation of pSmad3 via activation of PKG, quiescent PASMCs cultured on slides were pretreated with PKG inhibitors KT5823 (1 µM) or Rp-8-Br-cGMP (50 µM), or vehicle for 15 min before adding ANP (1 µM) or cGMP (1 mM). Cells were incubated with TGF-β1 for an additional 60 min, then fixed and stained with selective anti-pSmad3, as in Experiment 3. Nuclear translocation of pSmad3 was assessed using confocal phase-contrast fluorescence microscopy, as in Experiment 3.
RNA isolation for Northern blot
PASMC were homogenized, and total RNA was extracted using the TRIZOL total RNA isolation reagent (Invitrogen Corp). Northern analysis was performed using a 32 Plabeled selective cDNA probes for PN, OPN, PAI-1 and GAPDH that had been generated in our laboratory by reverse transcription (RT) followed by the DNA 
Statistical analysis
Results were expressed as means ± SEM. Statistical analyses were carried out using the SigmaStat package (Jandel Scientific Software, San Rafael, CA) on a PC.
Statistical comparisons of mRNA levels were performed with the one-way analysis of variance (ANOVA) or unpaired t-test. If ANOVA results were significant, a post-hoc comparison among groups was performed with the Newman-Keuls test. Differences were reported as significant if the P value was < 0.05.
RESULTS
ANP and cGMP inhibit TGF-β1-stimulated PN, OPN and PAI-1 expression in PASMCs
Northern blot analysis demonstrated that PN and OPN mRNA expression 
cGMP does not inhibit TGF-β1-induced phosphorylation of Smad3 and Smad2 in PASMCs
Western blot analysis demonstrated that TGF-β1 treatment significantly increased pSmad3 and pSmad2 levels in PASMCs and that pretreatment with cGMP did not inhibit TGF-β1-induced phosphorylation of Smad3 or Smad2 in these cells.
Smad4 levels were not altered by either TGF-β1 or cGMP treatment ( Figure 2A ).
Neither cGMP nor TGF-β1 treatment altered total Smad2/3 levels in these cells ( Figure 2B ). These results indicate that activation of ANP-cGMP signaling does not block TGF-
β1-induced phosphorylation of Smad2 and Smad3 and thus that disruption of Smad2
and Smad3 phosphorylation does not account for the inhibitory effects of ANP and cGMP on TGF-β1-induced ECM expression.
ANP and cGMP inhibit TGF-β1-induced nuclear translocation of pSmad2 and pSmad3 in PASMCs
In vehicle treated cells, immunostaining of pSmad2 and pSmad3 was weak and distributed evenly in cytoplasm and nucleus, suggesting that pSmad2 and pSmad3 levels were low and without significant nuclear translocation ( Figures When PASMCs were exposed to TGF-β1 (1 ng/ml) for 5 to 360 min, the nuclear accumulation of pSmad2 and pSmad3 began at 15 min, peaked at 30 min (pSmad2) and 60 min (pSmad3), and decreased but did not reach pretreatment levels by 3 and 6
hrs of TGF-β1 treatment ( Figures 5C and 5D ). The maximal percentages of PASMCs with pSmad2 and pSmad3 nuclear translocation were 23% and 94%, respectively.
Pretreatment with cGMP (1 mM for 30 min) decreased both the peak and duration of TGF-β1-induced pSmad2 and pSmad3 nuclear translocation ( Figures 5C and 5D ). 
Inhibition of PKG attenuates
DISCUSSION
In the present study, we demonstrate for the first time that ANP has an antifibrogenic effect on PASMCs treated with TGF-β1. ANP and cGMP suppressed TGF-β-stimulated ECM gene expression by interfering with Smad signaling through a PKGdependent mechanism. The most striking finding of this study is that ANP and cGMP inhibit TGF-β1-induced nuclear translocation of pSmad2 and pSmad3, but not the TGF- 
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